<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35052416</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4425</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>28</Day></PubDate></JournalIssue><Title>Genes</Title><ISOAbbreviation>Genes (Basel)</ISOAbbreviation></Journal><ArticleTitle>Investigating the Genetic Profile of the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia (ALS-FTD) Continuum in Patients of Diverse Race, Ethnicity and Ancestry.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">76</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/genes13010076</ELocationID><Abstract><AbstractText>Preliminary evidence suggests that commonly used genetic tests may be less likely to identify a genetic etiology for ALS-FTD in patients of underrepresented race, ethnicity, and ancestry (REA), as compared to European REA. Patients of underrepresented REA may therefore be less likely to receive accurate and specific genetic counseling information and less likely to have access to gene-targeted therapies currently in clinical trials. We compiled outcome data from 1911 ALS-FTD patients tested at a commercial laboratory over a seven-year period for <i>C9orf72</i> hexanucleotide repeat expansion (HRE) alone or <i>C9orf72</i> and multigene sequencing panel testing. We compared the incidence of pathogenic (P), likely pathogenic (LP), and uncertain variants in <i>C9orf72</i> and other ALS-FTD genes, as well as age at testing, in patients of different REA. The diagnostic rate in patients of European REA (377/1595, 23.64%) was significantly higher than in patients of underrepresented REA (44/316, 13.92%) (<i>p</i> &lt; 0.001). Patients of European REA were more likely to have the <i>C9orf72</i> HRE (21.3%) than patients of underrepresented REA (10.4%) (<i>p</i> &lt; 0.001). The overall distribution of positive test outcomes in all tested genes was significantly different between the two groups, with relatively more P and LP variants in genes other than <i>C9orf72</i> identified in patients of underrepresented REA. The incidence of uncertain test outcomes was not significantly different between patients of European and underrepresented REA. Patients with positive test outcomes were more likely to be younger than those with negative or uncertain outcomes. Although <i>C9orf72</i> HRE assay has been advocated as the first, and in some cases, only genetic test offered to patients with ALS-FTD in the clinical setting, this practice may result in the reduced ascertainment of genetic ALS-FTD in patients of diverse REA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mesaros</LastName><ForeName>Maysen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43212, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neuroscience, Medical University of South Carolina, Charleston, SC 29425, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lenz</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>PreventionGenetics, Marshfield, WI 54449, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Woobeen</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-4154-5133</Identifier><AffiliationInfo><Affiliation>Division of Biostatistics, College of Public Health, The Ohio State University, Columbus, OH 43210, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Jordan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43212, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drury</LastName><ForeName>Luke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>PreventionGenetics, Marshfield, WI 54449, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roggenbuck</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43212, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Genes (Basel)</MedlineTA><NlmUniqueID>101551097</NlmUniqueID><ISSNLinking>2073-4425</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005006" MajorTopicYN="N">Ethnicity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076610" MajorTopicYN="Y">Genetic Profile</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044469" MajorTopicYN="N">Racial Groups</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">FTD</Keyword><Keyword MajorTopicYN="N">REA</Keyword><Keyword MajorTopicYN="N">genetics</Keyword></KeywordList><CoiStatement>Jennifer Roggenbuck receives research support from the ALS Association and consulting support from Ionis. The funders had no role in the design of this study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Luke Drury and Steven Lenz were employed by PreventionGenetics at the time of this study. </CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>21</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35052416</ArticleId><ArticleId IdType="pmc">PMC8775163</ArticleId><ArticleId IdType="doi">10.3390/genes13010076</ArticleId><ArticleId IdType="pii">genes13010076</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siddique N., Siddique T. Amyotrophic Lateral Sclerosis Overview. In: Adam M.P., Ardinger H.H., Pagon R.A., Wallace S.E., Bean L.J., Mirzaa G., Amemiya A., editors. GeneReviews&#xae;. University of Washington; Seattle, WA, USA: 1993.</Citation><ArticleIdList><ArticleId IdType="pubmed">20301623</ArticleId></ArticleIdList></Reference><Reference><Citation>Broce I.J., Castruita P.A., Yokoyama J.S. Moving Toward Patient-Tailored Treatment in ALS and FTD: The Potential of Genomic Assessment as a Tool for Biological Discovery and Trial Recruitment. Front. Neurosci. 2021;15:150. doi: 10.3389/fnins.2021.639078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.639078</ArticleId><ArticleId IdType="pmc">PMC7956998</ArticleId><ArticleId IdType="pubmed">33732107</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramzon Y.A., Fratta P., Traynor B.J., Chia R. The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Front. Neurosci. 2020;14:42. doi: 10.3389/fnins.2020.00042.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00042</ArticleId><ArticleId IdType="pmc">PMC7012787</ArticleId><ArticleId IdType="pubmed">32116499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S.-C., Polymenidou M., Cleveland D.W. Converging Mechanisms in ALS and FTD: Disrupted RNA and Protein Homeostasis. Neuron. 2013;79:416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Rechtman L., Jordan H., Wagner L., Horton D.K., Kaye W. Racial and ethnic differences among amyotrophic lateral sclerosis cases in the United States. Amyotroph. Lateral Scler. Front. Degener. 2014;16:65&#x2013;71. doi: 10.3109/21678421.2014.971813.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.971813</ArticleId><ArticleId IdType="pmc">PMC4389704</ArticleId><ArticleId IdType="pubmed">25482100</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan D., Jett&#xe9; N., Fiest K.M., Roberts J.I., Pearson D., Smith E.E., Roach P., Kirk A., Pringsheim T., Maxwell C.J. The Prevalence and Incidence of Frontotemporal Dementia: A Systematic Review. Can. J. Neurol. Sci. J. Can. Des Sci. Neurol. 2016;43:S96&#x2013;S109. doi: 10.1017/cjn.2016.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/cjn.2016.25</ArticleId><ArticleId IdType="pubmed">27307130</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts A.L., Johnson N.J., Chen J.T., Cudkowicz M.E., Weisskopf M.G. Race/ethnicity, socioeconomic status, and ALS mortality in the United States. Neurology. 2016;87:2300&#x2013;2308. doi: 10.1212/WNL.0000000000003298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003298</ArticleId><ArticleId IdType="pmc">PMC5135021</ArticleId><ArticleId IdType="pubmed">27742817</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B., Logroscino G., Boum&#xe9;diene F., Labrunie A., Couratier P., Babron M.-C., Leutenegger A.-L., Preux P.-M., Beghi E. Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin. Eur. J. Epidemiol. 2015;31:229&#x2013;245. doi: 10.1007/s10654-015-0090-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-015-0090-x</ArticleId><ArticleId IdType="pubmed">26458931</ArticleId></ArticleIdList></Reference><Reference><Citation>Qadri S., Langefeld C.D., Milligan C., Caress J.B., Cartwright M.S. Racial differences in intervention rates in individuals with ALS. Neurology. 2019;92:e1969&#x2013;e1974. doi: 10.1212/WNL.0000000000007366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007366</ArticleId><ArticleId IdType="pmc">PMC6511079</ArticleId><ArticleId IdType="pubmed">30918092</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R., Chi&#xf2; A., Traynor B.J. Novel genes associated with amyotrophic lateral sclerosis: Diagnostic and clinical implications. Lancet Neurol. 2018;17:94&#x2013;102. doi: 10.1016/S1474-4422(17)30401-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Roggenbuck J., Fong J.C. Genetic Testing for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Clin. Lab. Med. 2020;40:271&#x2013;287. doi: 10.1016/j.cll.2020.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cll.2020.05.002</ArticleId><ArticleId IdType="pubmed">32718499</ArticleId></ArticleIdList></Reference><Reference><Citation>Roggenbuck J., Quick A., Kolb S.J. Genetic testing and genetic counseling for amyotrophic lateral sclerosis: An update for clinicians. Genet. Med. 2017;19:267&#x2013;274. doi: 10.1038/gim.2016.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2016.107</ArticleId><ArticleId IdType="pubmed">27537704</ArticleId></ArticleIdList></Reference><Reference><Citation>Test. Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) Panel&#x2014;PreventionGenetics.  [(accessed on 24 November 2021)].  Available online:  https://www.preventiongenetics.com/testInfo?val=Amyotrophic+Lateral+Sclerosis+%28ALS%29+and+Frontotemporal+Dementia+%28FTD%29+Panel.</Citation></Reference><Reference><Citation>Mok K., Traynor B.J., Schymick J., Tienari P.J., Laaksovirta H., Peuralinna T., Myllykangas L., Chi&#xf2; A., Shatunov A., Boeve B.F., et al. The chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiol. Aging. 2012;33:209.e3&#x2013;209.e8. doi: 10.1016/j.neurobiolaging.2011.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.08.005</ArticleId><ArticleId IdType="pmc">PMC3312749</ArticleId><ArticleId IdType="pubmed">21925771</ArticleId></ArticleIdList></Reference><Reference><Citation>Pliner H.A., Mann D.M., Traynor B.J. Searching for Grendel: Origin and global spread of the C9ORF72 repeat expansion. Acta Neuropathol. 2014;127:391&#x2013;396. doi: 10.1007/s00401-014-1250-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1250-x</ArticleId><ArticleId IdType="pmc">PMC4545603</ArticleId><ArticleId IdType="pubmed">24496499</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E., Renton A.E., Mok K., Dopper E.G., Waite A., Rollinson S., Chio A., Restagno G., Nicolaou N., S&#xe1;nchez J.S., et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A cross-sectional study. Lancet Neurol. 2012;11:323&#x2013;330. doi: 10.1016/S1474-4422(12)70043-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., He J., Gao F.-B., Gitler A.D., Fan D. The epidemiology and genetics of Amyotrophic lateral sclerosis in China. Brain Res. 2018;1693:121&#x2013;126. doi: 10.1016/j.brainres.2018.02.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.02.035</ArticleId><ArticleId IdType="pmc">PMC6486791</ArticleId><ArticleId IdType="pubmed">29501653</ArticleId></ArticleIdList></Reference><Reference><Citation>Nel M., Agenbag G.M., Henning F., Cross H.M., Esterhuizen A., Heckmann J.M. C9orf72 repeat expansions in South Africans with amyotrophic lateral sclerosis. J. Neurol. Sci. 2019;401:51&#x2013;54. doi: 10.1016/j.jns.2019.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.04.026</ArticleId><ArticleId IdType="pmc">PMC6556408</ArticleId><ArticleId IdType="pubmed">31009932</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A., Battistini S., Calvo A., Caponnetto C., Conforti F.L., Corbo M., Giannini F., Mandrioli J., Mora G., Sabatelli M., et al. Genetic counselling in ALS: Facts, uncertainties and clinical suggestions. J. Neurol. Neurosurg. Psychiatry. 2013;85:478&#x2013;485. doi: 10.1136/jnnp-2013-305546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-305546</ArticleId><ArticleId IdType="pubmed">23833266</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon M.-J., Baek W., Ki C.-S., Kim H.Y., Koh S.-H., Kim J.-W., Kim S.H. Screening of the SOD1, FUS, TARDBP, ANG, and OPTN mutations in Korean patients with familial and sporadic ALS. Neurobiol. Aging. 2012;33:1017.e17&#x2013;1017.e23. doi: 10.1016/j.neurobiolaging.2011.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.12.003</ArticleId><ArticleId IdType="pubmed">22244934</ArticleId></ArticleIdList></Reference><Reference><Citation>Alavi A., Nafissi S., Rohani M., Zamani B., Sedighi B., Shamshiri H., Fan J.-B., Ronaghi M., Elahi E. Genetic analysis and SOD1 mutation screening in Iranian amyotrophic lateral sclerosis patients. Neurobiol. Aging. 2013;34:1516.e1&#x2013;1516.e8. doi: 10.1016/j.neurobiolaging.2012.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.09.006</ArticleId><ArticleId IdType="pubmed">23062701</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Desaro P., Johnston A., Ross O.A., Wszolek Z.K., Ertekin-Taner N., Graff-Radford N.R., Rademakers R., Boylan K. Novel p.Ile151Val mutation in VCP in a patient of African American descent with sporadic ALS. Neurology. 2011;77:1102&#x2013;1103. doi: 10.1212/WNL.0b013e31822e563c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31822e563c</ArticleId><ArticleId IdType="pmc">PMC3174069</ArticleId><ArticleId IdType="pubmed">21880997</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z.-Y., Liu M.-S., Li X.-G., Cui L.-Y. Screening of VCP mutations in Chinese amyotrophic lateral sclerosis patients. Neurobiol. Aging. 2013;34:1519.e3&#x2013;1519.e4. doi: 10.1016/j.neurobiolaging.2012.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.10.002</ArticleId><ArticleId IdType="pubmed">23102936</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Chio A., Traynor B.J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014;17:17&#x2013;23. doi: 10.1038/nn.3584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z.-Y., Cui L.-Y., Sun Q., Li X.-G., Liu M.-S., Xu Y., Zhou Y., Yang X.-Z. De novo FUS gene mutations are associated with juvenile-onset sporadic amyotrophic lateral sclerosis in China. Neurobiol. Aging. 2013;34:1312.e1&#x2013;1312.e8. doi: 10.1016/j.neurobiolaging.2012.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.09.005</ArticleId><ArticleId IdType="pubmed">23046859</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L., Pitout I.L., Fletcher S., Wilton S., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Jackson C.E., Kasarskis E.J., England J.D., Forshew D., Johnston W., Kalra S., Katz J.S., Mitsumoto H., Rosenfeld J., et al. Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1227&#x2013;1233. doi: 10.1212/wnl.0b013e3181bc01a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0b013e3181bc01a4</ArticleId><ArticleId IdType="pmc">PMC2764728</ArticleId><ArticleId IdType="pubmed">19822873</ArticleId></ArticleIdList></Reference><Reference><Citation>Klepek H., Nagaraja H., Goutman S.A., Quick A., Kolb S.J., Roggenbuck J. Lack of consensus in ALS genetic testing practices and divergent views between ALS clinicians and patients. Amyotroph. Lateral Scler. Front. Degener. 2019;20:216&#x2013;221. doi: 10.1080/21678421.2019.1582670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1582670</ArticleId><ArticleId IdType="pmc">PMC7085941</ArticleId><ArticleId IdType="pubmed">30931630</ArticleId></ArticleIdList></Reference><Reference><Citation>Vajda A., McLaughlin R.L., Heverin M., Thorpe O., Abrahams S., Al-Chalabi A., Hardiman O. Genetic testing in ALS. Neurology. 2017;88:991&#x2013;999. doi: 10.1212/WNL.0000000000003686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003686</ArticleId><ArticleId IdType="pmc">PMC5333513</ArticleId><ArticleId IdType="pubmed">28159885</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur K.C., Doyle C., Chi&#xf2; A., Traynor B.J. Use of Genetic Testing in Amyotrophic Lateral Sclerosis by Neurologists. JAMA Neurol. 2017;74:125&#x2013;126. doi: 10.1001/jamaneurol.2016.4540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.4540</ArticleId><ArticleId IdType="pmc">PMC7112760</ArticleId><ArticleId IdType="pubmed">27893008</ArticleId></ArticleIdList></Reference><Reference><Citation>Popejoy A.B., Fullerton S.M. Genomics is failing on diversity. Nat. Cell Biol. 2016;538:161&#x2013;164. doi: 10.1038/538161a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/538161a</ArticleId><ArticleId IdType="pmc">PMC5089703</ArticleId><ArticleId IdType="pubmed">27734877</ArticleId></ArticleIdList></Reference><Reference><Citation>Popejoy A.B., Ritter D.I., Crooks K., Currey E., Fullerton S.M., Hindorff L.A., Koenig B., Ramos E.M., Sorokin E.P., Wand H., et al. The clinical imperative for inclusivity: Race, ethnicity, and ancestry (REA) in genomics. Hum. Mutat. 2018;39:1713&#x2013;1720. doi: 10.1002/humu.23644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.23644</ArticleId><ArticleId IdType="pmc">PMC6188707</ArticleId><ArticleId IdType="pubmed">30311373</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndugga-Kabuye M.K., Issaka R.B. Inequities in multi-gene hereditary cancer testing: Lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African or Asian and Pacific Islander as compared to European. Fam. Cancer. 2019;18:465&#x2013;469. doi: 10.1007/s10689-019-00144-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10689-019-00144-6</ArticleId><ArticleId IdType="pmc">PMC6785397</ArticleId><ArticleId IdType="pubmed">31531760</ArticleId></ArticleIdList></Reference><Reference><Citation>Landry L.G., Rehm H.L. Association of Racial/Ethnic Categories with the Ability of Genetic Tests to Detect a Cause of Cardiomyopathy. JAMA Cardiol. 2018;3:341&#x2013;345. doi: 10.1001/jamacardio.2017.5333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2017.5333</ArticleId><ArticleId IdType="pmc">PMC5875303</ArticleId><ArticleId IdType="pubmed">29490334</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales J., Welter D., Bowler E.H., Cerezo M., Harris L.W., McMahon A.C., Hall P., Junkins H.A., Milano A., Hastings E., et al. A standardized framework for representation of ancestry data in genomics studies, with application to the NHGRI-EBI GWAS Catalog. Genome Biol. 2018;19:21. doi: 10.1186/s13059-018-1396-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-018-1396-2</ArticleId><ArticleId IdType="pmc">PMC5815218</ArticleId><ArticleId IdType="pubmed">29448949</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman-Andrews L. The known unknown: The challenges of genetic variants of uncertain significance in clinical practice. J. Law Biosci. 2017;4:648&#x2013;657. doi: 10.1093/jlb/lsx038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jlb/lsx038</ArticleId><ArticleId IdType="pmc">PMC5965500</ArticleId><ArticleId IdType="pubmed">29868193</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Grody W.W., Hegde M., Lyon E., Spector E., et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015;17:405&#x2013;423. doi: 10.1038/gim.2015.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2015.30</ArticleId><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashida S., Goodman M.S., Stafford J., Lachance C., Kaphingst K.A. Perceived familiarity with and importance of family health history among a medically underserved population. J. Community Genet. 2012;3:285&#x2013;295. doi: 10.1007/s12687-012-0097-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12687-012-0097-x</ArticleId><ArticleId IdType="pmc">PMC3461219</ArticleId><ArticleId IdType="pubmed">22569765</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J., Marcum C.S., Myers M., Koehly L.M. Racial differences in family health history knowledge of type 2 diabetes: Exploring the role of interpersonal mechanisms. Transl. Behav. Med. 2018;8:540&#x2013;549. doi: 10.1093/tbm/ibx062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/tbm/ibx062</ArticleId><ArticleId IdType="pmc">PMC6065534</ArticleId><ArticleId IdType="pubmed">29346616</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson T., Seo J., Griffith J., Baxter M., James A., Kaphingst K.A. &#x201c;You don&#x2019;t have to keep everything on paper&#x201d;: African American women&#x2019;s use of family health history tools. J. Community Genet. 2013;4:251&#x2013;261. doi: 10.1007/s12687-013-0138-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12687-013-0138-0</ArticleId><ArticleId IdType="pmc">PMC3666835</ArticleId><ArticleId IdType="pubmed">23397492</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand D., Polak M., Glass J.D., Fournier C.N. Comparison of Phenotypic Characteristics and Prognosis between Black and White Patients in a Tertiary ALS Clinic. Neurology. 2020;96:e840&#x2013;e844. doi: 10.1212/WNL.0000000000011396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011396</ArticleId><ArticleId IdType="pubmed">33372030</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein O., Gana-Weisz M., Nefussy B., Vainer B., Nayshool O., Bar-Shira A., Traynor B.J., Drory V.E., Orr-Urtreger A. High frequency of C9orf72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis patients from two founder populations sharing the same risk haplotype. Neurobiol. Aging. 2018;64:160.e1&#x2013;160.e7. doi: 10.1016/j.neurobiolaging.2017.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.12.015</ArticleId><ArticleId IdType="pmc">PMC5931221</ArticleId><ArticleId IdType="pubmed">29352617</ArticleId></ArticleIdList></Reference><Reference><Citation>Roggenbuck J., Rich K.A., Vicini L., Palettas M., Schroeder J., Zaleski C., Lincoln T., Drury L., Glass J.D. Amyotrophic Lateral Sclerosis Genetic Access Program. Neurol. Genet. 2021;7:e615. doi: 10.1212/NXG.0000000000000615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000615</ArticleId><ArticleId IdType="pmc">PMC8356701</ArticleId><ArticleId IdType="pubmed">34386583</ArticleId></ArticleIdList></Reference><Reference><Citation>Caswell-Jin J.L., Gupta T., Hall E., Petrovchich I.M., Mills M.A., Kingham K.E., Koff R., Chun N.M., Levonian P., Lebensohn A.P., et al. Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Genet. Med. 2018;20:234&#x2013;239. doi: 10.1038/gim.2017.96.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2017.96</ArticleId><ArticleId IdType="pubmed">28749474</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson R.E., Kuchenbaecker K., Walters R.K., Chen C.-Y., Popejoy A.B., Periyasamy S., Lam M., Iyegbe C., Strawbridge R.J., Brick L., et al. Genome-wide Association Studies in Ancestrally Diverse Populations: Opportunities, Methods, Pitfalls, and Recommendations. Cell. 2019;179:589&#x2013;603. doi: 10.1016/j.cell.2019.08.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.08.051</ArticleId><ArticleId IdType="pmc">PMC6939869</ArticleId><ArticleId IdType="pubmed">31607513</ArticleId></ArticleIdList></Reference><Reference><Citation>Couratier P., Lautrette G., Luna J., Corcia P. Phenotypic variability in amyotrophic lateral sclerosis. Rev. Neurol. 2021;177:536&#x2013;543. doi: 10.1016/j.neurol.2021.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2021.03.001</ArticleId><ArticleId IdType="pubmed">33902945</ArticleId></ArticleIdList></Reference><Reference><Citation>EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis. Andersen P.M., Abrahams S., Borasio G.D., de Carvalho M., Chio A., Van Damme P., Hardiman O., Kollewe K., Morrison K.E., et al. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS)&#x2014;Revised report of an EFNS task force. Eur. J. Neurol. 2011;19:360&#x2013;375. doi: 10.1111/j.1468-1331.2011.03501.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03501.x</ArticleId><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) Awareness of Family Health History as a Risk Factor for Disease&#x2014;United States, 2004. MMWR Morb. Mortal. Wkly. Rep. 2004;53:1044&#x2013;1047.</Citation><ArticleIdList><ArticleId IdType="pubmed">15538320</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaphingst K., Lachance C., Gepp A., D&#x2019;Anna L.H., Rios-Ellis B. Educating Underserved Latino Communities about Family Health History Using Lay Health Advisors. Public Health Genom. 2011;14:211&#x2013;221. doi: 10.1159/000272456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000272456</ArticleId><ArticleId IdType="pmc">PMC3136386</ArticleId><ArticleId IdType="pubmed">20051669</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P.R., Jones A.R., Opie-Martin S., Shatunov A., Iacoangeli A., Al Khleifat A., Smith B.N., Topp S., Morrison K.E., Shaw P.J., et al. Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias. J. Neurol. Neurosurg. Psychiatry. 2019;90:268&#x2013;271. doi: 10.1136/jnnp-2018-319089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319089</ArticleId><ArticleId IdType="pmc">PMC6518463</ArticleId><ArticleId IdType="pubmed">30270202</ArticleId></ArticleIdList></Reference><Reference><Citation>Popejoy A.B., Crooks K.R., Fullerton S.M., Hindorff L.A., Hooker G.W., Koenig B.A., Pino N., Ramos E.M., Ritter D.I., Wand H., et al. Clinical Genetics Lacks Standard Definitions and Protocols for the Collection and Use of Diversity Measures. Am. J. Hum. Genet. 2020;107:72&#x2013;82. doi: 10.1016/j.ajhg.2020.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2020.05.005</ArticleId><ArticleId IdType="pmc">PMC7332657</ArticleId><ArticleId IdType="pubmed">32504544</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>